Abstract
Peripheral B cell depletion via anti-CD20 treatment is a highly effective disease-modifying treatment in multiple sclerosis (MS) patients. A drawback of anti-CD20 treatment is poor immune responses to vaccination. While this can be mitigated by treatment interruption of at least six months prior to vaccination, the timing to resume treatment while maintaining subsequent vaccine responses remains undetermined. We characterized SARS-CoV-2 S-directed antibody and B cell responses throughout three BNT162b2 doses in MS patients, where the first two doses were given during treatment interruption. The last anti-CD20 rituximab infusion was given 1.3 years (median) prior to the first vaccine dose and re-administered four weeks after the second vaccine dose. After two vaccine doses, antibody-mediated responses in SARS-CoV-2-naïve MS patients were comparable to vaccinated healthy controls, albeit with greater variation. We could demonstrate that the response to the second dose of vaccination was predictive of a boost effect after a third dose, even after re-initiation of rituximab. MS patients also exhibited lower frequencies of Decay Accelerating Factor-negative memory B cells, a suggested proxy for germinal centre activity, than healthy individuals. Our findings also offer a first indication on the potential importance of antigenic stimulation of CD27-IgD- double negative B cells and the possible long-term impairment of germinal centre activity in rituximab-treated MS patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by grants from Umea University and Region Vasterbotten (RV-969133), Swedish Research Council (Dnr 2020-0625 to MF and Dnr 2021-04665 to CA), and the SciLifeLab National COVID-19 Research Program (VC-2020-0015) to MF.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Swedish Ethics Review Authority (Dnr 2021-00055, including approved amendments) and the Medical Products Agency Sweden. The study was registered at European Clinical Trials Database (EUDRACT Number 2021-000683-30) before the first patient was enrolled in the study. Umea University, Sweden served as trial sponsor and the Clinical Research Center, University Hospital of Northern Sweden was monitoring the study for regulatory compliance. All individuals were included after informed consent and data were stored in accordance with the EU General Data Protection Regulation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
